» Articles » PMID: 39078109

Self-reported Hepatitis B Testing Among Noninstitutionalized Adults in the United States Before the Implementation of Universal Screening, 2013-2017: A Nationwide Population-based Study

Overview
Journal J Viral Hepat
Specialty Gastroenterology
Date 2024 Jul 30
PMID 39078109
Authors
Affiliations
Soon will be listed here.
Abstract

In 2023, the US Centers for Disease Control and Prevention recommended universal screening for hepatitis B virus (HBV); however, the proportion of US adults screened before implementing this recommendation is unknown. We analysed nationally representative data from the National Health Interview Survey (2013-2017) on self-reported HBV testing among noninstitutionalized US adults ≥18 years. We employed Poisson logistic regression to identify factors associated with self-reported testing, using a conceptual framework that included four overarching factors: sociodemographic characteristics, healthcare access, health-seeking behaviours and experiences, and access to internet-based health information. Among 149,628 survey respondents, the self-reported HBV testing rate was 27.2% (95% CI 26.2-28.7) and increased by 1.7% from 2013 to 2017 (p = .006). In adjusted analysis, health-seeking behaviours and experiences had the strongest associations of self-reported testing including a history of hepatitis (AOR 2.68, 95% CI 1.92-3.73), receipt of hepatitis B vaccination (AOR 5.11, 95% CI 4.61-5.68) and prior testing for hepatitis C (AOR 9.14, 95% CI 7.97-10.48) and HIV (AOR 2.69, 95% CI 2.44-2.97). Other factors associated with testing included being male (AOR 1.14, 95% CI 1.03-1.26), ages 30-44 years (AOR 1.37, 95% CI 1.17-1.61), 45-60 years (AOR 1.55, 95% CI 1.30-1.80) and ≥60 years (AOR 1.53, 95% CI 1.28-1.84), residence in the Western US region (AOR 1.23, 95% CI 1.06-1.43), and access to internet-based health information (AOR 1.32, 95% CI 1.18-1.47). Being Hispanic was associated with lower odds of testing (AOR 0.80, 95% CI 0.66-0.97). These findings may help guide optimal HBV screening in the universal testing era.

References
1.
Olakunde B, Adeyinka D, Ndukwe C, Oladele T, Yahaya H, Ijaodola O . Antenatal hepatitis B screening in Nigeria: A comparative analysis with syphilis and HIV. Int J STD AIDS. 2021; 32(14):1290-1297. DOI: 10.1177/09564624211035922. View

2.
Maxwell A, Stewart S, Glenn B, Wong W, Yasui Y, Chang L . Theoretically informed correlates of hepatitis B knowledge among four Asian groups: the health behavior framework. Asian Pac J Cancer Prev. 2012; 13(4):1687-92. PMC: 3425378. DOI: 10.7314/apjcp.2012.13.4.1687. View

3.
Weinbaum C, Williams I, Mast E, Wang S, Finelli L, Wasley A . Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008; 57(RR-8):1-20. View

4.
Roberts H, Ly K, Yin S, Hughes E, Teshale E, Jiles R . Prevalence of HBV Infection, Vaccine-Induced Immunity, and Susceptibility Among At-Risk Populations: US Households, 2013-2018. Hepatology. 2021; 74(5):2353-2365. DOI: 10.1002/hep.31991. View

5.
Ramsey S, Unger J, Baker L, Little R, Loomba R, Hwang J . Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncol. 2019; 5(4):497-505. PMC: 6459217. DOI: 10.1001/jamaoncol.2018.6437. View